Digestive Diseases and Sciences

, Volume 53, Issue 11, pp 3012–3017 | Cite as

Deep Vein Thrombosis and Pulmonary Embolism in Cirrhosis Patients

  • David Gulley
  • Evgenia Teal
  • Attaya Suvannasankha
  • Naga Chalasani
  • Suthat Liangpunsakul
Original Paper


Background and Aims It is a commonly held notion that patients with cirrhosis do not suffer from deep vein thrombosis (DVT) or pulmonary embolism (PE) because they are naturally anticoagulated. However, to date, no studies have been carried out that objectively address this issue. We conducted a study to examine the relationship between cirrhosis and DVT/PE events. Methods A case–control study of patients seen at a tertiary care hospital was performed. Cases were hospitalized patients with biopsy and/or imaging plus clinical evidence of cirrhosis. Well-matched patients with no known evidence of cirrhosis served as controls. The DVT/PE events were identified by the international classification of disease-9 (ICD-9) codes and confirmed with radiographic/nuclear imaging. The Charlson Index was calculated to determine the comorbidity. The incidence of DVT/PE in cirrhotic patients was also compared to patients with chronic kidney disease (CKD), congestive heart failure (CHF), and solid organ cancers. Results This study consisted of 963 cirrhotics and 12,405 controls. Both the incidence of DVT/PE (1.8 vs. 0.9%, P = 0.007) and Charlson Index scores (3.2 ± 1.8 vs. 0.9 ± 1.5, P < 0.001) were higher in cirrhotics than in the controls. However, in the multivariate analysis, the presence of cirrhosis was not associated with DVT/PE [odds ratio (OR) 0.87, P = 0.06]. Partial thromboplastin time (PTT; OR 0.88, P = 0.04) and serum albumin (OR 0.47, P = 0.03) were the independent predictors of DVT/PE. The incidence of DVT/PE in cirrhotics (1.8%) was lower than that in patients with other medical illnesses: 7.1% in CKD, 7.8% in CHF, and 6.1% in cancers. Conclusion Patients with cirrhosis do not have a lower risk of DVT/PE than non-cirrhotic controls without other significant co-morbidities, such as CHF, CKD, and solid organ cancers. Partial thromboplastin time and serum albumin were found to be independently predictive of DVT/PE in cirrhotic patients.


Cirrhosis Deep vein thrombosis Pulmonary embolism 


  1. 1.
    Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, Berg CL (2006) Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 101:1524–1528. doi:10.1111/j.1572-0241.2006.00588.x PubMedCrossRefGoogle Scholar
  2. 2.
    Schrecengost JE, LeGallo RD, Boyd JC, Moons KG, Gonias SL, Rose CE Jr, Bruns DE (2003) Comparison of diagnostic accuracies in outpatients and hospitalized patients of D-dimer testing for the evaluation of suspected pulmonary embolism. Clin Chem 49:1483–1490. doi:10.1373/49.9.1483 PubMedCrossRefGoogle Scholar
  3. 3.
    Stanca CM, Bach N, Krause C, Tandon N, Freni MA, Gutierrez JA, Bodian C, Lopez J, Berk PD, Bodenheimer HC Jr., Branch AD, Odin JA (2005) Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. Am J Gastroenterol 100:1104–1109. doi:10.1111/j.1572-0241.2005.41315.x PubMedCrossRefGoogle Scholar
  4. 4.
    Jackson MR (1998) Diagnosis and management of venous thrombosis in the surgical patient. Semin Thromb Hemost 24[Suppl 1]:67–76PubMedGoogle Scholar
  5. 5.
    Overhage J, McDonald CJ, Suico JG (2000) The Regenstrief Medical Record System 2000: expanding the breadth and depth of a community wide EMR. Proc AMIA Symp 1173Google Scholar
  6. 6.
    McDonald CJ, Overhage JM, Tierney WM, Dexter PR, Martin DK, Suico JG, Zafar A, Schadow G, Blevins L, Glazener T, Meeks-Johnson J, Lemmon L, Warvel J, Porterfield B, Warvel J, Cassidy P, Lindbergh D, Belsito A, Tucker M, Williams B, Wodniak C (1999) The Regenstrief Medical Record System: a quarter century experience. Int J Med Inform 54:225–253. doi:10.1016/S1386-5056(99)00009-X PubMedCrossRefGoogle Scholar
  7. 7.
    American Cancer Society (2007) Cancer facts and figures 2007. Database online. American Cancer Society, Altlanta. Accessed 18 Jan 2007Google Scholar
  8. 8.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. doi:10.1016/0021-9681(87)90171-8 PubMedCrossRefGoogle Scholar
  9. 9.
    Charlson ME, Sax FL, MacKenzie CR, Braham RL, Fields SD, Douglas RG Jr (1987) Morbidity during hospitalization: can we predict it? J Chronic Dis 40:705–712 doi:10.1016/0021-9681(87)90107-X PubMedCrossRefGoogle Scholar
  10. 10.
    Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA (2007) Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 167:935–943. doi:10.1001/archinte.167.9.935 PubMedCrossRefGoogle Scholar
  11. 11.
    Calmus Y, Robert A (1992) Increased procoagulant activity in peripheral blood mononuclear cells from patients with liver cirrhosis. Thromb Res 68:103–108. doi:10.1016/0049-3848(92)90132-T PubMedCrossRefGoogle Scholar
  12. 12.
    Orlando M, Casalbore P, Camagna A, Lauro R, Tardella L, Hassan HJ (1982) Factor VII in liver cirrhosis. Haemostasis 11:73–78PubMedGoogle Scholar
  13. 13.
    Castelino DJ, Salem HH (1997) Natural anticoagulants and the liver. J Gastroenterol Hepatol 12:77–83. doi:10.1111/j.1440-1746.1997.tb00351.x PubMedCrossRefGoogle Scholar
  14. 14.
    Zurborn KH, Kirch W, Bruhn HD (1988) Immunological and functional determination of the protease inhibitors, protein C and antithrombin III, in liver cirrhosis and in neoplasia. Thromb Res 52:325–336. doi:10.1016/0049-3848(88)90073-4 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • David Gulley
    • 1
  • Evgenia Teal
    • 2
  • Attaya Suvannasankha
    • 3
  • Naga Chalasani
    • 1
  • Suthat Liangpunsakul
    • 1
    • 4
  1. 1.Division of Gastroenterology and HepatologyIndiana University Medical CenterIndianapolisUSA
  2. 2.The Regenstrief Institute for Health CareIndianapolisUSA
  3. 3.Division of Hematology and Oncology, Department of MedicineIndiana University School of MedicineIndianapolisUSA
  4. 4.Roudebush Veterans Administration Medical CenterIndianapolisUSA

Personalised recommendations